Protocolized proactive desmopressin plus 3% saline therapy for severe euvolemic hyponatremia in the wave of COVID-19: The local experience and the potential role of emergency departments

在新冠疫情期间,针对严重正常血容量性低钠血症,采用规范化的主动式去氨加压素联合3%生理盐水治疗:本地经验及急诊科的潜在作用

阅读:1

Abstract

BACKGROUND: Patients with severe euvolemic hyponatremia can be challenging to treat, and the COVID-19 pandemic has added to the complexity of the situation. METHODS: Data were collected from all patients treated in a local intensive care unit (ICU) with the protocolized proactive desmopressin plus 3% saline (PD-3 S) approach in March 2022. RESULTS: Six patients were treated with the protocol, whose initial serum sodium level (SNa) ranged from 98 to 108 mmol/L. SNa of one patient dropped further due to delayed initiation of protocolized PD-3 S because of access block. But otherwise, the protocol had been effective in achieving a controlled rise of SNa in all patients. No major complications have been observed, and the feedback from both medical and nursing staff was overall positive. CONCLUSION: This case series shows that the protocolized PD-3 S is safe and effective. This protocol is currently being used in two ICUs in our cluster. And our unit is currently working with the emergency department to initiate the protocol earlier, before ICU admission.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。